tiprankstipranks
Trending News
More News >
Ocular Therapeutix (OCUL)
NASDAQ:OCUL

Ocular Therapeutix (OCUL) Stock Statistics & Valuation Metrics

Compare
1,419 Followers

Total Valuation

Ocular Therapeutix has a market cap or net worth of $1.16B. The enterprise value is ―.
Market Cap$1.16B
Enterprise Value

Share Statistics

Ocular Therapeutix has 159,299,730 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding159,299,730
Owned by Insiders3.32%
Owned by Institutions50.44%

Financial Efficiency

Ocular Therapeutix’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -41.05%.
Return on Equity (ROE)-0.61
Return on Assets (ROA)-0.42
Return on Invested Capital (ROIC)-41.05%
Return on Capital Employed (ROCE)-0.41
Revenue Per Employee232.57K
Profits Per Employee-706.23K
Employee Count274
Asset Turnover0.14
Inventory Turnover1.85

Valuation Ratios

The current PE Ratio of Ocular Therapeutix is -6.98. Ocular Therapeutix’s PEG ratio is -0.71.
PE Ratio-6.98
PS Ratio0.00
PB Ratio4.49
Price to Fair Value4.29
Price to FCF-7.57
Price to Operating Cash Flow-8.21
PEG Ratio-0.71

Income Statement

In the last 12 months, Ocular Therapeutix had revenue of 63.72M and earned -193.51M in profits. Earnings per share was -1.22.
Revenue63.72M
Gross Profit58.10M
Operating Income-171.78M
Pretax Income-193.51M
Net Income-193.51M
EBITDA-176.14M
Earnings Per Share (EPS)-1.22

Cash Flow

In the last 12 months, operating cash flow was -145.46M and capital expenditures -2.97M, giving a free cash flow of -148.43M billion.
Operating Cash Flow-145.46M
Free Cash Flow-148.43M
Free Cash Flow per Share-0.93

Dividends & Yields

Ocular Therapeutix pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.72
52-Week Price Change23.10%
50-Day Moving Average7.42
200-Day Moving Average8.46
Relative Strength Index (RSI)48.23
Average Volume (3m)1.57M

Important Dates

Ocular Therapeutix upcoming earnings date is Aug 11, 2025, TBA Not Confirmed.
Last Earnings DateMay 5, 2025
Next Earnings DateAug 11, 2025
Ex-Dividend Date

Financial Position

Ocular Therapeutix as a current ratio of 10.66, with Debt / Equity ratio of 28.66%
Current Ratio10.66
Quick Ratio10.59
Debt to Market Cap0.05
Net Debt to EBITDA1.80
Interest Coverage Ratio-12.65

Taxes

In the past 12 months, Ocular Therapeutix has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Ocular Therapeutix EV to EBITDA ratio is -5.88, with an EV/FCF ratio of -7.61.
EV to Sales16.25
EV to EBITDA-5.88
EV to Free Cash Flow-7.61
EV to Operating Cash Flow-7.69

Balance Sheet

Ocular Therapeutix has $349.68M in cash and marketable securities with $76.22M in debt, giving a net cash position of -$273.46M billion.
Cash & Marketable Securities$349.68M
Total Debt$76.22M
Net Cash-$273.46M
Net Cash Per Share-$1.72
Tangible Book Value Per Share$1.99

Margins

Gross margin is 90.66%, with operating margin of -269.57%, and net profit margin of -303.67%.
Gross Margin90.66%
Operating Margin-269.57%
Pretax Margin-303.67%
Net Profit Margin-303.67%
EBITDA Margin-276.42%
EBIT Margin-282.36%

Analyst Forecast

The average price target for Ocular Therapeutix is $17.56, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$17.56
Price Target Upside140.55% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast-0.33%
EPS Growth Forecast-3.59%

Scores

Smart Score6
AI Score47
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis